Allogeneic stem cell transplantation has an underappreciated role in the management of intermediate-grade non-Hodgkin's lymphoma. It provides several advantages over autologous stem cell transplantation including provision of a lymphoma-free graft, reduced rates of secondary myelodysplastic syndrome and leukemia, and a potentially curative graft-versus-lymphoma effect. When applied to chemosensitive patients, the lower relapse rates and reasonable long-term outcomes make allogeneic transplantation a promising therapy to pursue. Patient populations, such as those with bone marrow involvement or very high-risk disease, can be identified as having suboptimal outcomes after autotransplantation and may benefit from such an approach. While the exact role of allogeneic stem cell transplantation remains to be determined, broad recommendations can be suggested for the management of patients with intermediate-grade lymphoma. New approaches to allogeneic transplantation, including the use of matched-unrelated donors and reduced-intensity conditioning regimens, may expand the applicability of this potentially curative modality. Bone Marrow Transplantation (2003) 31, 953-960. 
Against the trend of most human cancers, the incidence of and mortality from non-Hodgkin's lymphoma continues to increase. 1 For patients with aggressive histology (or intermediate-grade) subtypes, anthracycline-based chemotherapy cures approximately 40-60% of patients, 2, 3 but for those with high-risk features at diagnosis or with relapsed disease, cure rates remain suboptimal. Intensification of therapy with autologous stem cell transplantation (autoSCT) has a well-defined role in the management of patients with relapsed intermediate-grade lymphoma, [4] [5] [6] but not yet as initial therapy in those with high-risk disease. [7] [8] [9] [10] [11] [12] [13] Allogeneic stem cell transplantation (alloSCT)
has traditionally been applied to the management of the leukemias, but now appears to have an emerging role in low-grade lymphoma. 14 The use of alloSCT in the management of aggressive histology lymphomas remains controversial and in many centers is somewhat unfashionable. This article will focus on evidence supporting a role for alloSCT in intermediate-grade lymphoma (Table 1) .
Why consider alloSCT?
Graft versus lymphoma (GvLy) effect -does it exist for aggressive histology lymphoma?
In myeloid malignancies 15, 16 and as the basis of nonmyeloablative approaches, 17 alloSCT provides a unique graft-versus-tumor effect that contributes significantly to disease eradication and cure. Evidence for a GvLy effect has been examined in several reports and is presented in Table 2 .
Reduced relapse after allografts, compared to autografts and syngeneic transplants, is consistent with the presence of a graft-versus-tumor effect. A common finding of single arm cohort studies of alloSCT is a lower than expected relapse rate, but the lack of a uniform patient population and a comparator group limits any conclusions. The importance of comparing lymphoma patients with the same histologic subtype is illustrated in a study showing that histologic grade significantly influences disease progression with relapse rates at 2years of 9, 39 and 80% for low-, intermediate-and high-grade histology, respectively. 18 Disease status is also important as shown in a subgroup analysis of 22 patients with chemosensitive, relapsed aggressive lymphoma undergoing alloSCT. 19 A relapse rate of only 13% was noted, reduced compared to that of the entire group and considerably less than seen in a similar cohort of patients treated with autoSCT in the PARMA trial. 4 Comparative trials of autoSCT and alloSCT have unfortunately revealed conflicting results regarding relapse rates (Table 2) , analyses being particularly limited by small sample size.
Relapse is also not consistently decreased in the presence of GVHD 19, [20] [21] [22] [23] [24] [25] (Table 2 ) nor increased after transplantation with T-cell-depleted marrow. [26] [27] [28] Isolated but impressive cases of response to withdrawal of immunosuppression and to donor leukocyte infusions have also been reported in some, 19, 29, 30 but not most cases.
Selection bias
As illustrated by these data, assessment of relapse rates after allogeneic transplantation for intermediate-grade disease is compromised methodologically by a number of factors. Selection bias likely plays a major role in the reported outcomes and may influence the results both positively and negatively. In general, cohorts of alloSCT patients are likely to be younger and have excellent performance status, but on the other hand they often have more advanced disease, more refractory disease, more prior therapy (including autoSCT) and increased bone marrow involvement. Outcomes following alloSCT could certainly be better if these latter poor-risk patients were not treated.
Biologically, differences in relapse between alloSCT and autoSCT may be due not only to GvLy, but potentially to graft contamination by lymphoma cells or by greater efficacy of the TBI-based regimens generally used in alloSCT. To circumvent the issue of graft contamination in assessing relapse rates, Bierman et al 28 recently completed an IBMTR/EBMTR comparison of syngeneic transplants with autoSCT and alloSCT for lymphoma. Compared to syngeneic transplants, there was no difference in relapse rates following allografts in the intermediategrade lymphoma category, suggesting that there was no significant GvLy effect.
In comparison with myeloid malignancies and low-grade lymphoma treated with alloSCT, the evidence supporting a graft-versus-tumor effect in intermediate-grade lymphoma is less compelling, and while such an effect may exist, its contribution to prevention of relapse appears much less substantial. It is possible that with intermediate-grade lymphomas, the slow-acting GvLy effect is overridden by the rapidity of growth of the tumor.
Avoidance of therapy-related MDS/AML
AlloSCT has the advantage of using 'fresh' stem cells that have not been previously exposed to chemotherapeutic agents or radiation. The rate of secondary MDS/AML after alloSCT appears to be quite low, 31, 32 particularly in comparison to that after autoSCT, where the incidence of secondary marrow malignancy ranges from 1 to 25%. 33 
Provision of a 'clean' graft
The other advantage of using cells from an allogeneic donor is that they are not contaminated with lymphoma cells. While the contribution of transplanted occult lymphoma cells to relapse post-autoSCT is still unclear, 34, 35 sensitive techniques have revealed persisting disease in marrow 36 and peripheral blood grafts. 35, 37 The use of an allogeneic donor avoids these potential issues and would seem preferable for those who have persisting marrow involvement after salvage chemotherapy. Similarly the small but significant population of patients who fail to obtain an autologous graft because of stem cell depletion induced by prior therapy are obvious candidates for alloSCT.
Disadvantages of alloSCT

Morbidity and mortality of alloSCT
As seen with other transplant indications, any reduction in relapse achieved with alloSCT is offset by mortality attributable to the treatment itself. Early reports detailed high nonrelapse mortality, often in the range of 20-50%, 20, 22, 38 and in the largest published series of patients allografted for aggressive lymphoma, 19 32 of the 73 patients died from nonrelapse causes. It must be remembered, however, that these patients are in general more heavily pretreated than those in comparable reports of autoSCT.
The morbidity associated with allogeneic transplantation is also well recognized. The need for immunosuppression, complications of conditioning, GVHD and infections can result in substantial long-term complications and the need for prolonged and sometimes intensive medical supervision. There is a significant impact on the quality of life. While such problems are distinctly less in the short-term after autoSCT, long-term survivors of autotransplantation can suffer from debilitating fatigue and neurocognitive problems that are likely underappreciated. 39 
Age and donor restrictions
Obviously, alloSCT is limited by the availability of a suitably matched donor and has greater restrictions regarding recipient age, performance status and organ function than autoSCT. Increasing the donor pool via MUD or haploidentical transplants, and increasing the recipient population suitable for alloSCT via nonmyeloablative approaches is being explored in clinical trials.
Cost constraints
Stem cell transplantation is an expensive way to deliver curative therapy to patients with malignant disease. 40 While formal cost-utility comparisons are not available, there is no doubt that autoSCT is cheaper than alloSCT, so the use of alloSCT should be restricted to indications where the outcome following autoSCT is likely to be inferior.
Where are the randomized studies?
Finally, alloSCT suffers from a lack of randomized trials demonstrating superiority over other therapy. On the other hand, autoSCT has a single well-designed, if small, randomized controlled trial 4 demonstrating superiority of autoSCT compared to standard chemotherapy for relapsed chemosensitive intermediate-grade lymphoma. Of note, patients older than 60 years of age, primary nonresponders and those with bone marrow or CNS disease at relapse were excluded from this trial. No randomized evidence supports the use of autoSCT in these patient subsets.
Results of alloSCT
Assessment of the role of alloSCT in aggressive nonHodgkin's lymphoma is compromised by the paucity of quality trials in the literature. There are no randomized clinical trials of alloSCT vs autoSCT or conventional chemotherapy, nor do they seem likely. Most reports include highly heterogeneous patient cohorts with varying histologies (low-, intermediate-and high-grade nonHodgkin's lymphoma as well as Hodgkin's disease) and varying stages of disease (from patients in first complete remission to those in chemorefractory late relapse). The majority of reports have extremely few patients with intermediate-grade disease and only two published papers have 430 patients with aggressive histology in the alloSCT cohort. 19, 22 Table 3 details select single-arm cohort studies detailing specific outcomes for patients with aggressive non-Hodgkin's lymphoma. While it is difficult to draw firm conclusions from these reports, they do demonstrate that long-term disease-free survival is possible following alloSCT even though transplant-related mortality remains higher than that seen generally with autoSCT. Dhedin et al 19 have published the largest series of alloSCT for aggressive non-Hodgkin's lymphoma (Burkitt's and lymphoblastic lymphoma excluded). When the analysis was confined to 22 patients in chemosensitive relapse, the progression-free survival was 60%, a result that compares favorably with most autoSCT series. In a recent report detailing single center experience of allografting lymphoma, the Vancouver group 31 noted an overall survival of 37% in 43 patients with intermediate-grade histology, some of whom were primary induction failures.
The role of alloSCT and autoSCT for patients with aggressive NHL has been examined by a number of different comparative methodologies and is presented in Table 4 . These reports, primarily from registry data, provide some guidance on the relative merits of the two approaches. A case-controlled study by the EBMT 22 matched 101 patients with lymphoma undergoing alloSCT with 101 patients undergoing autoSCT for disease status and stage at transplant, histological grade, transplant conditioning, age, sex and time from diagnosis to transplant. Of these, 43 patients in each cohort had intermediate-grade lymphoma. Nonrelapse mortality was less for autoSCT patients (28 vs 14%, P ¼ 0.008), but there was no significant difference in progression-free survival or relapse rates. The EBMT more recently compared alloSCT and autoSCT using multivariate analysis to identify and correct for prognostic variables. 42 Of the 764 patients undergoing alloSCT, 272 had intermediate-grade disease with resultant 30% nonrelapse mortality, 43% progressionfree survival and 50% overall survival. In comparison with 9488 autoSCT patients, relapse was reduced (P ¼ 0.0006) but overall survival was significantly worse (P ¼ 0.0173) because of the higher transplant-related mortality in the alloSCT cohort.
Bierman et al 28 recently completed an analysis comparing syngeneic, auto and alloSCT drawing patients from the EBMTR, IBMTR and ABMTR. Of patients with intermediate-grade histology 31 , 1597 and 220 underwent syngeneic, auto and alloSCT, respectively. The 5-year diseasefree survival was significantly worse for recipients of T-cellreplete allogeneic grafts compared to syngeneic grafts (31 vs 42%, P ¼ 0.03), but there were no significant differences between syngeneic and autologous transplants. Similar findings were present with respect to overall survival.
Examination of other comparative studies of allo SCT vs autoSCT for lymphoma reveals that no specific outcomes are reported for the aggressive histology patients, usually because of small numbers in the alloSCT cohort. 20, 21, 23, 38, 43 Overall, the above outcomes reported for aggressive nonHodgkin's lymphoma are quite respectable and not dissimilar to that seen after autoSCT.
Importance of chemosensitivity
The importance of chemosensitivity in determining outcome after alloSCT for aggressive lymphoma has been repeatedly demonstrated across most studies and is the most consistent predictor of relapse, event-free and overall survival. [19] [20] [21] [22] [23] [24] [25] 27, 38, 44, 45 Those refractory to salvage chemotherapy at the time of transplant generally have eventfree survival less than 25%, and in some cases no event-free survival 20, 22 because of both increased rates of relapse and increased transplant-related mortality. This pattern is not dissimilar to that seen with autoSCT, suggesting that there is only a limited role for alloSCT to overcome chemoresistance.
When to transplant?
A critical issue in managing a potential transplant candidate with aggressive lymphoma is when to intervene in the disease course with alloSCT. As a general rule, Table 3 Single-arm cohort studies detailing outcome of alloSCT for X20 patients with aggressive histology non-Hodgkin's lymphoma Int-grade=intermediate-grade non-Hodgkin's lymphoma; NRM=nonrelapse mortality; PFS=progression-free survival; EFS=event-free survival; OS=overall survival.
Allogenic transplantation for aggressive NHL P Mollee et al alloSCT should be reserved until conventional chemotherapy is highly likely to fail, but before the patient experiences the effects of advanced stage disease. Also, given the lower morbidity and cost associated with autoSCT, alloSCT should be reserved for when autoSCT is also more likely to fail. Transplanting patients early in the disease course is likely to reduce relapse rates just as it does in other hematological malignancies; however, one is reluctant to expose patients in remission to a therapy with a high initial mortality rate. With scant data regarding allografting intermediate-grade lymphomas in first remission, alloSCT should not be routinely offered to these patients. It would seem reasonable, however, to prospectively study target populations at a high risk of failure.
Patients who fail to respond to primary induction chemotherapy may also represent a cohort suitable for alloSCT. These patients have a poor prognosis, even with autoSCT, [46] [47] [48] [49] although recently a number of groups have demonstrated that autoSCT can effectively salvage about 50% of patients sensitive to second-line chemotherapy. [50] [51] [52] Preliminary data suggest that alloSCT may be effective for patients with induction failure, 19, 31 although the effect of chemosensitivity has not been formally assessed in this population.
Patients with chemosensitive relapsed aggressive nonHodgkin's lymphoma are ideal candidates for alloSCT, especially if autoSCT is precluded because of inadequate stem cell collection or bone marrow involvement. While autoSCT is currently the preferred therapy, the role of alloSCT has probably been underestimated in these patients, and a prospective comparative trial is required to formally assess the two modalities. While results for patients who have relapsed after autoSCT are sobering, alloSCT may benefit highly select patients, particularly those with excellent performance status, younger age and nonaggressive relapse. [53] [54] [55] Widening the applicability of alloSCT
Pushing back the age barrier
Older patients tolerate intensive therapy less well than younger patients. While autografts are routinely offered to patients up to the age of 65 years, 56,57 more caution has been employed when considering older patients for alloSCT. Rapoport et al 58 found comparable outcomes following alloSCT for patients aged less than or greater than 45 years. An EBMT analysis found advanced age to be an independent poor risk factor, but noted decreasing transplant-related mortality despite the increasing average age of transplant recipients. 59 Such findings have encouraged the application of alloSCT to older patients, with some investigators concluding that there is no upper age limit for hematopoietic stem cell transplantation. 60 
MUD BMT
With only 30-40% of patients having a matched-related donor available, MUD transplants may increase the applicability of alloSCT. Two registry reports describe outcomes for patients with aggressive histology lymphoma. The IBMTR 61 reported a series of 158 patients, of whom 50 had intermediate-grade lymphoma. For the whole group, day 100 mortality was 45% and for the intermediate-grade group 2-year progression-free survival was 35%. Those with chemosensitive disease had a trend to improved progression-free survival at 2 years (40 vs 24% for chemosensitive vs refractory, P ¼ 0.07). The EBMT has also reported their experience of 56 patients undergoing MUD BMT for lymphoma, 26 of whom were adults with aggressive non-Hodgkin's lymphoma. 62 Transplant-related mortality was 42% and progression-free survival at 2 years was 16%. These reports indicate that while long-term survival is achievable for select patients, transplant-related mortality remains unacceptably high, limiting wider application of MUD transplants.
Nonmyeloablative SCT
The high nonrelapse mortality in most series of lymphoma allografts has prompted exploration of nonmyeloablative transplants as a means of circumventing early conditioningrelated mortality and morbidity. Initial encouraging results have been reported in abstract form by Khouri et al, 63 who treated 15 patients with aggressive relapsed non-Hodgkin's lymphoma using a nonmyeloablative regimen. Despite patients being heavily pretreated (including four who had failed a prior autoSCT), day 100 transplant-related mortality was 0% and the 2-year progression-free and overall survival were 61 and 71%, respectively. Spitzer et al 64 also reported initial results of 20 patients with heavily pretreated diffuse large B-cell lymphoma who underwent nonmyeloablative alloSCT. While day 100 transplant-related mortality was again 0%, early progression-free survival was only 25%. A UK collaborative group examined the outcome of 70 patients with non-Hodgkin's lymphoma treated with Campath, fludarabine and melphalan nonmyeloablative conditioning. 65 Transplant-related mortality was 19% and event-free survival was significantly worse for those with high-grade as opposed to low-grade histology (22 vs 65%), the latter finding also demonstrated in a retrospective analysis of EBMT data. 66 The same group also reported 38 patients with relapsed disease postautoSCT who received the same nonmyeloablative conditioning. In total, 10 of these had aggressive lymphomas, of whom only two are in complete remission at a median follow-up of 14 months. There were no responders to three DLI infusions given for progressive disease in the aggressive lymphoma patients. It is possible that the GvLy effect is not sufficient to compensate for the omission of intensive therapy in providing disease control. Until results mature, this modality should only be explored in the context of clinical trials.
Conclusions
The exact role of alloSCT in intermediate-grade nonHodgkin's lymphoma continues to be defined. A suggested approach to these patients is outlined in Figure 1 . The application of high-dose therapy, whether it utilizes allogeneic or autologous stem cells, to aggressive lymphomas in first remission remains investigational. Patients with relapsed or primary refractory disease should undergo salvage therapy to assess chemosensitivity. If reasonable outcomes are to be expected after alloSCT, it should not be offered to patients with chemorefractory disease. Given the demonstrated feasibility, the advantage of an uncontaminated stem-cell graft, the lower than expected relapse rates and the comparable outcomes in larger series, alloSCT is a promising modality for chemosensitive relapsed or primary refractory intermediate-grade lymphoma and should be compared to autoSCT in prospective clinical trials. Currently, however, evidence supports autoSCT as a curative therapy for these patients. Those who have persisting bone marrow involvement or who fail stem cell collection are candidates for alloSCT, as are select patients who relapse after autoSCT. Finally, new approaches currently being explored in clinical trials, including the use of matched-unrelated donors and reduced-intensity conditioning regimens, are expanding the frontiers of allogeneic transplantation.
